Dysbindin-1, BDNF, and GABAergic Transmission in Schizophrenia

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2022 Jul 11

PMID 35815020

Authors

Rachel Jun

Wen Zhang

Nicholas J Beacher

Yan Zhang

Yun Li

Da-Ting Lin

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a psychiatric disorder characterized by hallucinations, anhedonia, disordered thinking, and cognitive impairments. Both genetic and environmental factors contribute to schizophrenia. Dysbindin-1 () and brain-derived neurotrophic factor () are both genetic factors associated with schizophrenia. Mice lacking showed behavioral deficits similar to human patients suffering from schizophrenia. DTNBP1 plays important functions in synapse formation and maintenance, receptor trafficking, and neurotransmitter release. DTNBP1 is co-assembled with 7 other proteins into a large protein complex, known as the biogenesis of lysosome-related organelles complex-1 (BLOC-1). Large dense-core vesicles (LDCVs) are involved in the secretion of hormones and neuropeptides, including BDNF. BDNF plays important roles in neuronal development, survival, and synaptic plasticity. BDNF is also critical in maintaining GABAergic inhibitory transmission in the brain. Two studies independently showed that DTNBP1 mediated activity-dependent BDNF secretion to maintain inhibitory transmission. Imbalance of excitatory and inhibitory neural activities is thought to contribute to schizophrenia. In this mini-review, we will discuss a potential pathogenetic mechanism for schizophrenia involving DTNBP1, BDNF, and inhibitory transmission. We will also discuss how these processes are interrelated and associated with a higher risk of schizophrenia development.

Citing Articles

Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases.

Romero Garavito A, Diaz Martinez V, Juarez Cortes E, Negrete Diaz J, Montilla Rodriguez L Front Neurol. 2025; 15:1505879.

PMID: 39935805 PMC: 11810746. DOI: 10.3389/fneur.2024.1505879.

The protective effect of angiotensin II type I receptor blocker (valsartan) on behavioral impairment, NLRP3, BDNF, and oxidative stress in the brain tissue of ovariectomized female rats.

Erdem S, Ozacmak H, Turan I, Ergenc M Physiol Rep. 2024; 12(20):e70003.

PMID: 39443283 PMC: 11498971. DOI: 10.14814/phy2.70003.

What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia.

Correll C, Tusconi M, Carta M, Dursun S Biomolecules. 2024; 14(8).

PMID: 39199294 PMC: 11353083. DOI: 10.3390/biom14080906.

Loss of dysbindin-1 in excitatory neurons in mice impacts NMDAR-dependent behaviors, neuronal morphology and synaptic transmission in the ventral hippocampus.

Bhardwaj S, Nath M, Wong T, Srivastava L Sci Rep. 2024; 14(1):15239.

PMID: 38956130 PMC: 11219769. DOI: 10.1038/s41598-024-65566-4.

Epigenome-wide association study on methamphetamine dependence.

Shirai T, Okazaki S, Tanifuji T, Otsuka I, Horai T, Mouri K Addict Biol. 2024; 29(3):e13383.

PMID: 38488760 PMC: 11061849. DOI: 10.1111/adb.13383.

References

Jia J, Zhao J, Hu Z, Lindberg D, Li Z . Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat Neurosci. 2013; 16(11):1627-36. PMC: 3832846. DOI: 10.1038/nn.3542. View

Balu D, Coyle J . Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev. 2010; 35(3):848-70. PMC: 3005823. DOI: 10.1016/j.neubiorev.2010.10.005. View

Iizuka Y, Sei Y, Weinberger D, Straub R . Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci. 2007; 27(45):12390-5. PMC: 6673263. DOI: 10.1523/JNEUROSCI.1689-07.2007. View

Xu H, Jeong H, Tremblay R, Rudy B . Neocortical somatostatin-expressing GABAergic interneurons disinhibit the thalamorecipient layer 4. Neuron. 2013; 77(1):155-67. PMC: 3556168. DOI: 10.1016/j.neuron.2012.11.004. View

Kubota Y, Kawaguchi Y . Dependence of GABAergic synaptic areas on the interneuron type and target size. J Neurosci. 2000; 20(1):375-86. PMC: 6774130. View

Talbot K, Louneva N, Cohen J, Kazi H, Blake D, Arnold S . Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One. 2011; 6(3):e16886. PMC: 3046962. DOI: 10.1371/journal.pone.0016886. View

Papaleo F, Yang F, Garcia S, Chen J, Lu B, Crawley J . Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry. 2010; 17(1):85-98. PMC: 3388848. DOI: 10.1038/mp.2010.106. View

Lee H, Nemecek D, Schindler C, Smith W, Ghirlando R, Steven A . Assembly and architecture of biogenesis of lysosome-related organelles complex-1 (BLOC-1). J Biol Chem. 2011; 287(8):5882-90. PMC: 3285357. DOI: 10.1074/jbc.M111.325746. View

Dickman D, Davis G . The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science. 2009; 326(5956):1127-30. PMC: 3063306. DOI: 10.1126/science.1179685. View

10.

Ma X, Fei E, Fu C, Ren H, Wang G . Dysbindin-1, a schizophrenia-related protein, facilitates neurite outgrowth by promoting the transcriptional activity of p53. Mol Psychiatry. 2011; 16(11):1105-16. DOI: 10.1038/mp.2011.43. View

11.

Wentzel C, Delvendahl I, Sydlik S, Georgiev O, Muller M . Dysbindin links presynaptic proteasome function to homeostatic recruitment of low release probability vesicles. Nat Commun. 2018; 9(1):267. PMC: 5773495. DOI: 10.1038/s41467-017-02494-0. View

12.

Mullin A, Sadanandappa M, Ma W, Dickman D, VijayRaghavan K, Ramaswami M . Gene dosage in the dysbindin schizophrenia susceptibility network differentially affect synaptic function and plasticity. J Neurosci. 2015; 35(1):325-38. PMC: 4287151. DOI: 10.1523/JNEUROSCI.3542-14.2015. View

13.

Tang J, Zhou J, Fan J, Li X, Shi Y, Gu N . Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol Psychiatry. 2003; 8(8):717-8. DOI: 10.1038/sj.mp.4001287. View

14.

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

15.

Xu T, Wang Y, Li Z, Huang J, Lui S, Tan S . Heritability and familiality of neurological soft signs: evidence from healthy twins, patients with schizophrenia and non-psychotic first-degree relatives. Psychol Med. 2015; 46(1):117-23. DOI: 10.1017/S0033291715001580. View

16.

Subburaju S, Benes F . Induction of the GABA cell phenotype: an in vitro model for studying neurodevelopmental disorders. PLoS One. 2012; 7(3):e33352. PMC: 3310062. DOI: 10.1371/journal.pone.0033352. View

17.

Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N . Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet. 2004; 13(21):2699-708. DOI: 10.1093/hmg/ddh280. View

18.

Ayhan Y, McFarland R, Pletnikov M . Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. Prog Neurobiol. 2015; 136:1-27. PMC: 4707068. DOI: 10.1016/j.pneurobio.2015.10.002. View

19.

Larimore J, Tornieri K, Ryder P, Gokhale A, Zlatic S, Craige B . The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. Mol Biol Cell. 2011; 22(24):4854-67. PMC: 3237628. DOI: 10.1091/mbc.E11-07-0592. View

20.

Cox M, Tucker A, Tang J, Talbot K, Richer D, Yeh L . Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009; 8(4):390-7. PMC: 2774142. DOI: 10.1111/j.1601-183X.2009.00477.x. View